LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Elanco Animal Health Inc

Gesloten

SectorGezondheidszorg

12.93 0.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.89

Max

12.99

Belangrijke statistieken

By Trading Economics

Inkomsten

75M

67M

Verkoop

173M

1.2B

K/W

Sectorgemiddelde

17.093

56.602

EPS

0.37

Winstmarge

5.616

Werknemers

9,000

EBITDA

86M

261M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+13.24% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.6B

6.4B

Vorige openingsprijs

12.78

Vorige sluitingsprijs

12.93

Nieuwssentiment

By Acuity

62%

38%

320 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Elanco Animal Health Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2025, 11:29 UTC

Acquisities, Fusies, Overnames

Elanco Sells Non-Core Asset to Blackstone for $295 Million

27 jun 2024, 14:34 UTC

Belangrijke Marktbewegers

Elanco Shares Retreat Over Zenrelia Warning Label Concerns

5 mei 2025, 11:14 UTC

Acquisities, Fusies, Overnames

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5 mei 2025, 10:50 UTC

Acquisities, Fusies, Overnames

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5 mei 2025, 10:49 UTC

Acquisities, Fusies, Overnames

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

9 jul 2024, 12:30 UTC

Acquisities, Fusies, Overnames

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9 jul 2024, 12:29 UTC

Acquisities, Fusies, Overnames

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

9 jul 2024, 12:28 UTC

Acquisities, Fusies, Overnames

Elanco Animal Health: $1.05B-$1.1B Net Proceeds Available for Debt Paydown in 3Q >ELAN

9 jul 2024, 12:28 UTC

Acquisities, Fusies, Overnames

Elanco Completes Sale of Aqua Business to Merck >ELAN MRK

Peer Vergelijking

Prijswijziging

Elanco Animal Health Inc Prognose

Koersdoel

By TipRanks

13.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.63 USD  13.24%

Hoogste 20 USD

Laagste 10 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Elanco Animal Health Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technische score

By Trading Central

9.77 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

320 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.